New lung cancer cocktail aims to outperform standard care

NCT ID NCT07583511

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two drug combinations for people with extensive-stage small-cell lung cancer who haven't had prior treatment. One group gets teniposide, cisplatin, and serplulimab; the other gets the standard etoposide, cisplatin, and serplulimab. The goal is to see which combo works better at delaying cancer growth. About 90 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: teniposide, cisplatin, serplulimab
What this could lead to: If it works, this could offer a more effective first-line treatment option for extensive-stage small-cell lung cancer, potentially improving how long patients live without their cancer getting worse.
What could go wrong: This is an early phase 2 trial with only 90 people, so results are not definitive. The new combination may not be better than the standard, and could have unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Locations

SUN-YAT-SEN University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.